BiopharmaTrend.com

A fresh viewpoint on drug discovery, pharma, and biotech

Subscribe | Become an author | Author LogIn

Topic: ‘Artificial Intelligence’


Confluence of Technologies Can Bring “Virtual Pharmacology” to the Next Level

   by Andrii Buvailo    37
Confluence of Technologies Can Bring “Virtual Pharmacology” to the Next Level

In contrast to early days of drug discovery, when ideas about new medicines were born primarily via “serendipitous trial-and-error” approach, or mere luck, modern drug design is a more conscious process -- owing to increased understanding of disease mechanisms and the underlying biology, advents of combinatorial chemistry, high-throughput screening, and many other experimental techniques, and, of course, advances in computational methods.

Presenting a New Paradigm for Drug Discovery: Combining Computational Biophysics and AI through MatchMaker

   by Naheed Kurji    395
Presenting a New Paradigm for Drug Discovery: Combining Computational Biophysics and AI through MatchMaker

In this Special Perspective, our fourth in an ongoing series, we will be presenting MatchMaker™, a novel deep proteome screening technology that we have developed and validated over the past 2 years to identify DTIs. MatchMaker builds on Cyclica’s passions of combining protein, chemistry, and genomic data, and augmenting it with high performance computing and algorithm development supported on the cloud.

2018: AI Is Surging In Drug Discovery Market

   by Andrii Buvailo    8873
2018: AI Is Surging In Drug Discovery Market

Updated: 10.01.2019. Newly added content is marked in the text with "Update" sign.

The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a surge of activity in this area over the last several years. In 2018, things are getting even “hotter” with the increase in the amount of partnerships, investments and other important events, summarized and grouped below into “mini-trends”.

Democratizing Artificial Intelligence For Pharmaceutical Research

   by Andrii Buvailo    517
Democratizing Artificial Intelligence For Pharmaceutical Research

Over the last five years the interest of pharmaceutical professionals towards machine learning (ML) and artificial intelligence (AI) has measurably increased -- while only one “AI-related” research collaboration involving “big pharma” appeared in the news in 2013, the number of such events increased up to 21 in 2017 alone, involving some of the top pharma players like GSK, Sanofi, Abbvie, Genentech, etc.